Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA).

Trial Profile

Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Triamcinolone (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms IBeTA
  • Most Recent Events

    • 01 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top